These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 180375)

  • 21. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters.
    Morgan LR; Schein PS; Woolley PV; Hoth D; Macdonald J; Lippman M; Posey LE; Beazley RW
    Cancer Treat Rep; 1976 Oct; 60(10):1437-43. PubMed ID: 191185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The clinical value of hormone receptors in the treatment of breast neoplasms].
    Trams G
    Med Lab (Stuttg); 1979 Nov; 32(11):263-9. PubMed ID: 542183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrine therapy of breast and prostate cancer.
    Manni A
    Endocrinol Metab Clin North Am; 1989 Jun; 18(2):569-92. PubMed ID: 2663486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Internal endocrine therapy of breast cancer].
    Yoshida M; Miura S
    Gan To Kagaku Ryoho; 1984 May; 11(5):989-98. PubMed ID: 6372698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The current status of endocrine therapy in the palliative treatment of the metastasizing breast carcinoma in women].
    Nowakowski H
    Chirurg; 1968 Jun; 39(6):258-63. PubMed ID: 5697277
    [No Abstract]   [Full Text] [Related]  

  • 26. Hormonal therapy for metastatic male breast cancer.
    Kantarjian H; Yap HY; Hortobagyi G; Buzdar A; Blumenschein G
    Arch Intern Med; 1983 Feb; 143(2):237-40. PubMed ID: 6824391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamoxifen therapy of metastatic breast cancer.
    Manni A
    J Lab Clin Med; 1987 Mar; 109(3):290-9. PubMed ID: 2950193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormonal approaches to breast cancer treatment and prevention: an overview.
    Vogel CL
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):2-9. PubMed ID: 8824459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocrine management of breast cancer.
    Schneider PG; Jackisch C; Brandt B
    Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():115-27. PubMed ID: 7874188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The surgical implications of estrophile protein estimations in carcinoma of the breast.
    Walt AJ; Singhakowinta A; Brooks SC; Cortez A
    Surgery; 1976 Oct; 80(4):506-12. PubMed ID: 184556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Possibilities and limitations of endocrine therapy of metastasizing breast cancer].
    Nowakowski H
    Verh Dtsch Ges Inn Med; 1967; 73():505-18. PubMed ID: 5591802
    [No Abstract]   [Full Text] [Related]  

  • 33. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The state of hormone and chemotherapy in breast neoplasms].
    Brunner KW
    Schweiz Med Wochenschr; 1978 Sep; 108(35):1338-50. PubMed ID: 210499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hormonodependence and hormonosensibility of the gynecological neoplasias. III. The breast carcinoma].
    Sesti F; Farne C
    Patol Clin Ostet Ginecol; 1985; 13(4):273-82. PubMed ID: 12281788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical considerations of hormonal receptors in breast cancer.
    Skandalakis LJ; Winokur SH; Gray SW
    Am Surg; 1979 Sep; 45(9):556-60. PubMed ID: 228575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antiestrogens: a new endocrine treatment possibility in metastasizing breast neoplasms. Experiences of the Swiss Cooperative Cancer Study Group with tamoxifen].
    Jungi WF; Alberto P; Wagenknecht L; Cavalli F; Martz G; Brunner KW
    Schweiz Med Wochenschr; 1978 Aug; 108(34):1317-21. PubMed ID: 694481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J; Sommer A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.